MARKET

SESN

SESN

Sesen Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5353
+0.0209
+4.06%
Opening 10:27 05/24 EDT
OPEN
0.5098
PREV CLOSE
0.5144
HIGH
0.5379
LOW
0.4773
VOLUME
1.38M
TURNOVER
490.01K
52 WEEK HIGH
6.04
52 WEEK LOW
0.3650
MARKET CAP
106.77M
P/E (TTM)
2.122
1D
5D
1M
3M
1Y
5Y
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Zacks · 1d ago
Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Zacks · 1d ago
BRIEF-Sesen Bio -FDA Granted Request For Meeting To Discuss Remaining Items For Additional Phase 3 Trial Related To Potential BLA Resubmission For Vicineum
reuters.com · 4d ago
Merck (MRK) Outperforms Industry This Year So Far: Here's Why
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Zacks · 5d ago
AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene
Zacks · 05/17 13:27
Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates
The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.
Zacks · 05/17 13:08
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
Zacks · 05/16 18:23
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
Zacks · 05/16 13:28
More
No Data
Learn about the latest financial forecast of SESN. Analyze the recent business situations of Sesen Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
0.00%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SESN stock price target is 1.780 with a high estimate of 3.000 and a low estimate of 0.5600.
High3.000
Average1.780
Low0.5600
Current 0.5361
EPS
Actual
Estimate
-0.030.090.210.33
Q2 2021
Q3 2021
Q4 2021
    0
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 113
Institutional Holdings: 63.97M
% Owned: 32.07%
Shares Outstanding: 199.46M
TypeInstitutionsShares
Increased
26
9.69M
New
18
1.15M
Decreased
29
7.73M
Sold Out
26
3.40M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.82%
Pharmaceuticals & Medical Research
-0.14%
Key Executives
Non-Executive Chairman/Independent Director
Jay Duker
President/Chief Executive Officer/Director
Thomas Cannell
Chief Financial Officer/Treasurer
Monica Forbes
Chief Technology Officer
Glen MacDonald
Chief Accounting Officer/Controller
Elly Ryu
General Counsel/Secretary
Mark Sullivan
Director
Peter Honig
Director
Michael Jewett
Independent Director
Carrie Bourdow
Independent Director
Jason Keyes
No Data
No Data
About SESN
Sesen Bio, Inc. is a late-stage clinical company providing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. Its product pipeline includes Vicinium, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process.

Webull offers kinds of Sesen Bio Inc stock information, including NASDAQ:SESN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SESN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SESN stock methods without spending real money on the virtual paper trading platform.